Scilex Holding (SCLX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
24 Jun, 2026Opening remarks and agenda
The meeting was called to order by the Executive Chairperson, who introduced key officers and the independent auditor, and outlined the virtual meeting format and Q&A procedures.
The agenda included the election of one Class I director, ratification of the independent auditor, and approval of an amendment to the 2022 Equity Incentive Plan.
Voting procedures and rules of conduct were reviewed, with instructions for proxy and live voting.
Board and executive committee updates
The Board nominated Dorman Followwill for re-election as Class I director, with no other nominations received.
Shareholder proposals
No shareholder proposals were received for this year's meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Scilex Holding
- Q2 2026 saw a $115M net loss, declining revenue, and ongoing liquidity risks.SCLX
Q2 2026 - 2025 net revenue fell 46% to $30.3M, with a $374.1M net loss and significant liquidity risk.SCLX
Q4 2025 - 2024 revenue rose to $56.6M, but losses and liquidity risks threaten ongoing operations.SCLX
Q4 2024 - Non-opioid pain company with $56.6M 2024 revenue, ongoing losses, and $100M equity line.SCLX
Registration filing - Non-opioid pain company with high debt, recurring losses, and urgent need for new funding.SCLX
Registration filing - Q2 2025 revenue dropped 40% year-over-year, with deepening losses and liquidity concerns.SCLX
Q2 2025 - Q1 2026 net loss widened to $45.7M on higher costs; liquidity and going concern risks persist.SCLX
Q1 2026 - Significant net loss and cash constraints in Q3 2025 amid strategic shifts and high financing costs.SCLX
Q3 2025 - Registration covers 3.5M shares for resale from warrant exercises tied to a $100M loan commitment.SCLX
Registration filing